Vitamin D in health and disease.
Vitamin D functions in the body through both an endocrine mechanism (regulation of calcium absorption) and an autocrine mechanism (facilitation of gene expression). The former acts through circulating calcitriol, whereas the latter, which accounts for more than 80% of the metabolic utilization of the vitamin each day, produces, uses, and degrades calcitriol exclusively intracellularly. In patients with end-stage kidney disease, the endocrine mechanism is effectively disabled; however, the autocrine mechanism is able to function normally so long as the patient has adequate serum levels of 25(OH)D, on which its function is absolutely dependent. For this reason, calcitriol and its analogs do not constitute adequate replacement in managing vitamin D needs of such patients. Optimal serum 25(OH)D levels are greater than 32 ng/mL (80 nmol/L). The consequences of low 25(OH)D status include increased risk of various chronic diseases, ranging from hypertension to diabetes to cancer. The safest and most economical way to ensure adequate vitamin D status is to use oral dosing of native vitamin D. (Both daily and intermittent regimens work well.) Serum 25(OH)D can be expected to rise by about 1 ng/mL (2.5 nmol/L) for every 100 IU of additional vitamin D each day. Recent data indicate that cholecalciferol (vitamin D(3)) is substantially more potent than ergocalciferol (vitamin D(2)) and that the safe upper intake level for vitamin D(3) is 10,000 IU/d.
Creighton University, Omaha, NE 68131, USA. rheaney@creighton.edu
Robert P
RP
Heaney
D000284:Administration, Oral; D000818:Animals; D002117:Calcitriol / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000209:etiology / Q000378:metabolism; D002762:Cholecalciferol / Q000378:metabolism; D003141:Communicable Diseases / Q000209:etiology / Q000378:metabolism; D003920:Diabetes Mellitus / Q000209:etiology / Q000378:metabolism; D004872:Ergocalciferols / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000378:metabolism; D009369:Neoplasms / Q000209:etiology / Q000378:metabolism; D018673:Nutrition Policy; D010024:Osteoporosis / Q000209:etiology / Q000378:metabolism; D018167:Receptors, Calcitriol / Q000378:metabolism; D015398:Signal Transduction; D014807:Vitamin D / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity; D014808:Vitamin D Deficiency / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D014815:Vitamins / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity
D004872:Ergocalciferols; D018167:Receptors, Calcitriol; D014815:Vitamins; D014807:Vitamin D; D002762:Cholecalciferol; D002117:Calcitriol